BioSpace News Archive

PDL BioPharma, Inc. (“PDL” or “the Company”) (Nasdaq: PDLI) announces that it will release its second quarter 2020 financial results for the period ended June 30, 2020, on Thursday, August 6, 2020, after market close.

Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2020.

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 13, 2020 at 5:00 p.m. ET to report second quarter 2020 financial results and discuss recent business highlights.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter and first half 2020.

-Findings show that MIS-C is a post-infectious syndrome distinct from Kawasaki disease and may help guide treatment decisions --

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it will report financial results for the second quarter ended June 30, 2020, and provide a corporate update on Monday, August 3, 2020

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company will release second quarter 2020 financial results on Thursday, August 6, 2020 after the close of market.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2020 financial results and provided an update on the company, including its second quarter progress with eganelisib (also known as IPI-549), the company’s first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibition.

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2020 and provided an update on recent business progress.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2020.